US FDA's Biosimilars Chief Leah Christl Plans Departure

A departure date has yet to be determined for the associate director of therapeutic biologics, who helped negotiate and implement the biosimilar user fee program.

FDA entrance sign 2016

The US FDA is preparing for the departure of the head of its biosimilars program, Leah Christl, who has helped shape the pathway since its infancy.

Christl, associate director of therapeutic biologics in the Office of New Drugs, is expected to leave the agency soon, although...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics